Showing results (961-970 of 1,107) with videos related to

Sort By:
Pageof 111
BJU International|January 18, 2019
Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?Chad A Reichard, Yaw A Nyame, Debasish Sundi, et al.
Patient Preference and Adherence|November 12, 2021
Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative StudyJudith J Stephenson, Jonathon Colby Gable, Rebekah Zincavage, et al.
BMC Cancer|May 18, 2013
The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumorsLee S Rosen, Lara Lipton, Timothy J Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRPE K Rowinsky, L Smith, Y M Wang, et al.
ACS Medicinal Chemistry Letters|June 7, 2023
TMPRSS2 Inhibitor Discovery Facilitated through anAmanda L Peiffer, Julie M Garlick, Yujin Wu, et al.
Plos Neglected Tropical Diseases|June 16, 2021
Orthobunyaviruses in the Caribbean: Melao and Oropouche virus infections in school children in Haiti in 2014Maha A Elbadry, Ricardo Durães-Carvalho, Gabriela M Blohm, et al.
The Oncologist|August 10, 2019
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF AlterationsAditya Bardia, Mrinal Gounder, Jordi Rodon, et al.
Genes, Brain, and Behavior|October 22, 2021
A quantitative trait variant in Gabra2 underlies increased methamphetamine stimulant sensitivityLisa R Goldberg, Emily J Yao, Julia C Kelliher, et al.
G3 (Bethesda, Md.)|July 21, 2019
Cyfip1 Haploinsufficiency Increases Compulsive-Like Behavior and Modulates Palatable Food Intake in Mice: Dependence on Cyfip2 Genetic Background, Parent-of Origin, and SexRichard K Babbs, Jacob A Beierle, Qiu T Ruan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2015
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate CancerBruce Montgomery, Mario A Eisenberger, Matthew B Rettig, et al.
Pageof 111